Spruce Biosciences, Inc. (SPRB) Stock Price & Analysis
Spruce Biosciences, Inc. (SPRB) fell 3.88% to USD 47.13 as of June 11, 2026 at 08:44 UTC, according to Nexqual real-time market data.
SPRB last closed at USD 49.03; the session ranged USD 47.13–50.38 on volume of 33,960 shares. Market capitalization is $129.71M, with a 52-week range of USD 7–838.13 (NCM). Source: Nexqual, June 11, 2026 at 08:44 UTC.
Key Statistics (as of June 11, 2026 at 08:44 UTC)
| Price | USD 47.13 |
|---|---|
| Change | ▼ 3.88% (down) |
| Previous Close | USD 49.03 |
| Open | USD 48.53 |
| Day Range | USD 47.13 – 50.38 |
| 52-Week Range | USD 7 – 838.13 |
| Volume | 33,960 shares |
| Market Cap | $129.71M |
| Exchange | NCM |
Technical Analysis (SPRB)
Nexqual's technical model rates SPRB "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 11, 2026 at 08:44 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 44.35 (neutral) |
| vs SMA50 | Below (USD 57.35) |
| MACD | -2.1 (negative) |
Analyst Ratings (SPRB)
Wall Street analysts rate SPRB "Strong Buy" based on 6 analysts, with a mean price target of USD 154.17 (range USD 120–230), per Nexqual as of June 11, 2026 at 08:44 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 154.17 |
| High Target | USD 230 |
| Low Target | USD 120 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (SPRB)
| EPS Estimate | USD -5.82 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -8.94 vs est -6.12 ▼ miss |
| 2025-12-31 | USD -9.58 vs est -9.57 ▼ miss |
| 2025-09-30 | USD -14.58 vs est -12.31 ▼ miss |
| 2025-06-30 | USD -3.5 vs est -18 ▲ beat |
Source: Nexqual, June 11, 2026 at 08:44 UTC.
Financials & Fundamentals (SPRB)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -148.85% |
| Debt / Equity | 20.56 |
| Current Ratio | 4.67 |
| Total Cash | $54.08M |
| Total Debt | $7.12M |
| Free Cash Flow | $-13.36M |
Source: Nexqual, June 11, 2026 at 08:44 UTC.
Financial Health Score (SPRB)
Nexqual rates Spruce Biosciences, Inc.'s overall financial health "Weak" across five dimensions, as of June 11, 2026 at 08:44 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $54M cash vs $7M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$29M |
| Efficiency | Critical — ROE -149%, ROA -37.2% |
Ownership (SPRB)
| Insider Ownership | +3.51% |
|---|---|
| Institutional Ownership | +31.06% |
| Shares Outstanding | 2.75M |
| Float | 2.65M |
| Short % of Float | +8.88% |
Source: Nexqual, June 11, 2026 at 08:44 UTC.
Leadership (SPRB)
Spruce Biosciences, Inc. is led by Javier Szwarcberg M.D., M.P.H. (age 55), CEO & Director, per Nexqual as of June 11, 2026 at 08:44 UTC.
| CEO & Director | Javier Szwarcberg M.D., M.P.H. (age 55) |
|---|---|
| Executive Chairman | Michael G. Grey (age 72) |
| President & CFO | Samir M. Gharib (age 43) |
| Chief Medical Officer & Director | Kirk Ways (age 72) |
| Senior Vice President of Clinical Development Operations | Bruno Gagnon BPHARM, M.Sc. (age 56) |
Major Backers & Investors (SPRB)
Notable institutional backers of Spruce Biosciences, Inc. include Ikarian Capital, LLC, Millennium Management, Citadel, according to Nexqual as of June 11, 2026 at 08:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ikarian Capital, LLC | 21.55% |
| Millennium Management | 19.87% |
| Citadel | 12.43% |
| Adar1 Capital Management, LLC | 10.41% |
| Alyeska Investment Group, L.p. | 9.18% |
| Wellington Management | 8.67% |
| Boothbay Fund Management, LLC | 7.47% |
| Balyasny Asset Management LP | 7.1% |
Source: Nexqual, June 11, 2026 at 08:44 UTC.
From Spruce Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
- The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B.
- It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns.
- In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | USD 20.15 | ▼ 3.63% |
| ABVX | Abivax SA | USD 98.03 | ▼ 3.45% |
| ONMD | OneMedNet Corp | USD 0.6 | ▼ 13.17% |
| CWD | CaliberCos Inc. | USD 0.89 | ▲ 5.83% |
| QMMM | QMMM Holdings Limited | USD 119.4 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 11, 2026 at 08:44 UTC. This page is informational and not investment advice.